B+
Bull case
25%
Probability
Target price
$0.75
Analysis reference price unavailable
Analysis 2026-10-09 · RankAlpha Sentiment Codex
KTTA
Pasithea TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$0.39
Analysis reference price unavailable
Analysis 2026-10-09 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.22
Analysis reference price unavailable
Analysis 2026-10-09 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-09
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+71.8
Score
AI commentary
The packet has no recent-news, social, options, short-interest or analyst-revision coverage; zero sentiment fields denote unavailable measures, not neutral readings. The dated company presentations improve catalyst visibility versus the prior monitoring view, but the deterministic prior remains negative and clinical outcomes are highly uncertain. No verified post-announcement price-reaction evidence is available.
RankAlpha Sentiment Codex - 2026-10-09
Open full AI memoEvidence flagged
small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-10-23eventPAS-004 advanced-cancer data at ESMOHigh impact
Pasithea plans to present Phase 1 safety and pharmacokinetic data on October 23. The full abstract has not yet been released; the presentation may clarify whether earlier observations hold in a larger dataset. [#IR-2026-07-21] Company announcement.
2026-11-13eventFirst public adult NF1 Part A clinical dataHigh impact
Pasithea scheduled cutaneous-neurofibroma and plexiform-neurofibroma presentations for November 12–13. These are initial Phase 1/1b data, not a registrational efficacy readout. [#IR-2026-09-14] Company announcement.
2027-08-14catalystDevelopment spending and future capital needsHigh impact
The June 2026 10-Q reported $45.7 million of cash and cash equivalents and $9.5 million of first-half operating cash use. Management expected funding for at least 12 months from the filing but said significant additional funds would eventually be needed. The date is an estimated reassessment point, not a scheduled financing. [#10-Q-2026-08-14] SEC filing.
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-09 • Updated nightlySource: Internal modelMethodology